New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTHSP, AKRX, UTHR, MDVN, CBST, ALKS, SLXP, JAZZ, AUXL, NPSPLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
News For ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR From The Last 14 Days
Check below for free stories on ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 9, 2014
10:10 EDTMDVNOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
09:28 EDTUTHRUnited Therapeutics shares undervalued, says Argus
Subscribe for More Information
08:42 EDTMDVNMedivation upgraded at Bernstein
Subscribe for More Information
08:17 EDTNPSPNPS Pharmaceuticals likely volatile on briefing docs, says FBR Capital
Subscribe for More Information
06:51 EDTALKSAlkermes management to meet with Leerink
Subscribe for More Information
06:43 EDTMDVNMedivation upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information
September 8, 2014
14:37 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
Subscribe for More Information
12:40 EDTHSPPar Pharmaceutical resumes shipment of generic Precedex Injection
Subscribe for More Information
11:05 EDTNPSPOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
08:33 EDTHSPHospira confirms FY14 EPS view $2.30-$2.50, consensus $2.41
Subscribe for More Information
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZ, SLXPJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:47 EDTNPSPOptions with increasing implied volatility
Subscribe for More Information
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
10:32 EDTNPSPNPS Pharmaceuticals September volatility increases into PDUFA
Subscribe for More Information
September 4, 2014
13:12 EDTHSPFDA posts approval of Hospira's Milrinone Lactate
Reference Link
10:45 EDTNPSPNPS drops after Feuerstein tweets about interview offer
Subscribe for More Information
10:06 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
NPS Pharmaceuticals September call option implied volatility is at 96, October is at 71, November is at 68; compared to its 26-week average of 64 according to Track Data, suggesting large near term price movement into PDUFA for Natpara on September 12.
08:17 EDTAKRXAkorn price target raised to $40 from $26 at Leerink
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use